Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Shares Outstanding (Weighted Average) (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Shares Outstanding (Weighted Average) readings, the most recent being $108.7 million for Q4 2022.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 121.26% to $108.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $108.7 million, a 121.26% increase, with the full-year FY2022 number at $108.7 million, up 121.26% from a year prior.
  • Shares Outstanding (Weighted Average) hit $108.7 million in Q4 2022 for Cardiol Therapeutics, up from $47.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $108.7 million in Q4 2022 to a low of $25.2 million in Q4 2020.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $47.8 million (2022), compared with a mean of $46.9 million.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 121.26% in 2022, down 39.37% in 2022.
  • Cardiol Therapeutics' Shares Outstanding (Weighted Average) stood at $25.2 million in 2020, then skyrocketed by 94.9% to $49.1 million in 2021, then surged by 121.26% to $108.7 million in 2022.
  • The last three reported values for Shares Outstanding (Weighted Average) were $108.7 million (Q4 2022), $47.8 million (Q3 2022), and $48.6 million (Q2 2022) per Business Quant data.